D3.2 Dissemination Action Plan · 2017-03-31 · D3.2 Dissemination Action Plan PU Page 2 Version 1.1 “This project has received funding from the European Union’s Horizon 2020

D3.2 Dissemination Action Plan

PU Page 1 Version 1.1

“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Grant Agreement No 675451“

Grantagreementno.675451

CompBioMed

ResearchandInnovationActionH2020-EINFRA-2015-1

Topic:CentresofExcellenceforComputingApplications

D3.2DisseminationActionPlan

WorkPackage: 3Duedateofdeliverable: Month03Actualsubmissiondate: 30/November/2016Startdateofproject: October,012016 Duration:36monthsLeadbeneficiaryforthisdeliverable:CBKContributors:UPF,BSC,UNIGE,UvA

Projectco-fundedbytheEuropeanCommissionwithintheH2020Programme(2014-2020)

DisseminationLevelPU Public YES

CO Confidential,onlyformembersoftheconsortium(includingtheCommissionServices)

CI Classified,asreferredtoinCommissionDecision2001/844/EC

Ref. Ares(2016)7105718 - 21/12/2016




DisclaimerThe content of this deliverable does not reflect the official opinion of the EuropeanUnion.Responsibilityfortheinformationandviewsexpressedhereinliesentirelywiththeauthor(s).TableofContents1 VersionLog...............................................................................................................32 Contributors.............................................................................................................33 DefinitionandAcronyms..........................................................................................44 ExecutiveSummary..................................................................................................55 Introduction.............................................................................................................55.1 DisseminationReports.....................................................................................65.2 DisseminationFunds........................................................................................6

6 TargetAudiences......................................................................................................66.1 Academia..........................................................................................................76.2 Industry............................................................................................................76.3 TheClinic..........................................................................................................86.4 RegionswithFewerHPCResources...............................................................106.5 GeneralAudiences.........................................................................................10

7 BrandingandDisseminationMaterials..................................................................117.1 ProjectLogo....................................................................................................117.2 Leaflets...........................................................................................................127.3 Posters............................................................................................................137.4 Presentations.................................................................................................137.5 ScientificPapers.............................................................................................147.6 OtherDisseminationMaterials......................................................................14

8 DisseminationChannels.........................................................................................148.1 TheCompBioMedWebsite.............................................................................148.2 SocialMedia...................................................................................................158.3 Mailinglists.....................................................................................................158.4 RelatedProjects.............................................................................................16

9 Events.....................................................................................................................169.1 EventOrganisation.........................................................................................169.2 EventParticipation.........................................................................................17

10 Training...............................................................................................................1811 AssociatePartnerEngagement..........................................................................1812 ReportingofDisseminationActivity...................................................................1813 OutputMeasurement........................................................................................1913.1 KeyPerformanceIndicators...........................................................................20

14 AftertheProject.................................................................................................2015 Conclusions........................................................................................................20




ListofTablesandFigures

Figure1:TheCompBioMedLogo(‘standard’version).........................................................................12Figure2:TheCompBioMedLogo('header’version)............................................................................12Figure3:CompBioMedSlideTempate................................................................................................13Figure4:TheCompBioMedTwitterAccount.......................................................................................15

1 VersionLogVersion Date Releasedby NatureofChange

V1.0 01/12/2016 HughMartin FirstDraft

V1.1 15/12/2016 HughMartin SecondDraft

V1.2 21/12/2016 PragnaKiri FinalDraft

2 ContributorsName Institution Role

HughMartin CBKSciCon Author

PeterVCoveney UCL Editor

GianniDeFabritiis UPF Editor

MarianoVazquez BSC Editor

RuthAris BSC Editor




3 DefinitionandAcronymsAcronyms Definitions

CoE CentreofExcellence

WP WorkPackage

KPI KeyPerformanceIndicator

HPC HighPerformanceComputing

SME SmallandMediumEnterprise

R&D ResearchandDevelopment

COST EuropeanCooperationinScienceandTechnology

MoU MemorandumofUnderstanding




4 ExecutiveSummaryComputational methods, based on human biology, are now reaching maturity in thebiomedicaldomain,renderingpredictivemodelsofhealthanddiseaseincreasinglyrelevanttoclinicalpracticebyprovidingapersonalizedaspect to treatment.Computerbasedmodellingandsimulation iswellestablished inthephysicalsciencesandengineering,wheretheuseofhigh performance computing (HPC) is now routine. CompBioMed is a user-driven Centre ofExcellence(CoE)inComputationalBiomedicine,designedtonurtureandpromotetheuptakeandexploitationofhighperformancecomputingwithinthebiomedicalmodellingcommunity.Ourusercommunitiescomefromacademia,industryandclinicalpractice.The CompBioMed Centre of Excellence in Biomedical Computing is distributed in nature,relyingoncollaborationwithin theproject, andalsowithexternal stakeholders.To thisend,CompBioMedwill develop and coordinate dissemination activities that enable us to engageexternal stakeholders inacademia,healthcareand industrywith theactivitiesof theproject.ThesuccessofCompBioMedreliesonitsmessages,developments,activities,andresultsbeingdisseminatedintothebiomedicalcommunity,aswellasgrowingandinteractingwithitsusercommunities.Thisdeliverable,D3.2:DisseminationActionPlan,actsasadetailedandcomprehensivereportonthedisseminationactionsthatwillbecarriedoutbytheproject.ThisdeliverableislinkedtoCompBioMed’sTask3.1:ProductionofaDisseminationActionPlan,andthereleaseofitisalsoMilestone2intheproject.Thisactionplanisa‘livingdocument’thatwillbeupdatedthroughouttheproject,asrequired.

5 IntroductionDissemination and outreach will play an important role in the CompBioMed Centre ofExcellence.Wewillpromotetheproject’soutcomes(publications,codes,whitepapers,pressreleases, flyers,posters,etc.) tostakeholders,be theymembersof thescientificcommunity,usercommunities,vendors,other industries,regulatoryauthorities,andrelatedinternationalprojects.A combination of dedicated media work, participation in conferences, preparation anddistribution of informationmaterial, and event organization will be used to implement ourimpact objectives. During the project, we will maintain the CompBioMed website for theexternalworldand for internalprojectcommunication,anddevelopasocialmediapresence(LinkedIn, Twitter, etc.).We will organise three training events (which will be addressed indetailinD3.3:TrainingPlan)andaworkshopwhichwewillattachtoalargeconference(suchasISCxy,SCxy,andsoon).TheeventswillpromoteCompBioMedresultsandsuccessstories.We will also produce dissemination materials such as white papers, which will becommunicatedtostandardsbodiesandrelevantinternationalevents.Thedisseminationactivitieswill encompassmanydifferentaspectsof theuseof 'computingbeyondthedesktop'withinthebiomedicalsciencescommunity.Wherepossible,wewilluse




existing material and courses, and early in the project a detailed training plan will beformulatedthatfurnishesfulldetails.TheCompBioMedConsortiumwill actively seekparticipation inall the relevant concertationactivitiesorganisedbyandfortheCommissioninthee-infrastructuredomain.

5.1 DisseminationReportsThree further deliverables will be produced during the project lifetime that will track andreportonthedisseminationactivityinCompBioMed:

• D3.4(andMilestone10):Firstreportondisseminationandtrainingmaterial,month12• D3.5:Secondreportontraininganddissemination,month24• D3.6:Finaltraininganddisseminationreport,month36

Each of these deliverables reports on the dissemination and training material and activityproduced by the project, and will trigger updates to the CompBioMed training plan anddisseminationactionplans.Thefinalreportwilldescribeareusablesetoftrainingmaterials,asdevelopedbyandusedduringtheproject.

5.2 DisseminationFundsCompBioMed has allocated funds for the consortium to use for dissemination purposes, asfollows:

• €6,000-CoveringCompBioMed’sattendanceatrelevantconferences;thesefundsareheldatUvA

• €24,000(3x€8,000)-Toruntrainingevents;thesefundsareheldatUvA• €10,000–Toorganisetheworkshopandproducedisseminationmaterials;thesefunds

areheldatUvA• €15,000-Forannualprojectmeetings;thesefundsareheldatUCL

6 TargetAudiencesThroughourdisseminationactions,wewilldisseminatetheproject’soutcomestoourvariousstakeholders,betheymembersofthescientificcommunity,userandhealthcarecommunities,vendors of hardware and software, other industries, regulatory authorities, and relatedinternationalprojects.TheresearchareasthatCompBioMedwill investigateanddirectly impactviatheCoEincludecardiovascular, neuro-musculoskeletal, and molecular medicine domains that account for asubstantialpercentageofcomputationalbiomedicine.However,throughourinclusiveoutwardfacing agenda and our strong training activities, we will actively improve access to suchcomputingapplicationsandexpertiseinthewiderbiomedicalcommunity,spawningmanynewcollaborativeactivitiesandinnovativeprojectswhichallrequireaccesstohighendcomputingcapabilities.




ThroughourCoE,wewill createahub thatpromoteshighqualitymodellingandsimulation,including the effective use of high performance computing across academia, industry and,clinicalpractice,meaningthattheimpactwillbewide-ranging.

6.1 AcademiaCompBioMed’s activitieswill naturally target academia, including students, researchers, andprofessors.Ourdisseminationchannels,organizedevents,andeventparticipation(describedinSections8and9)willreachawiderangeofacademicaudiences.Thiswillbestrengthenedthroughouracademiccorepartners:UniversityCollegeLondon,theUniversityofAmsterdam,the University of Edinburgh, SURFsara, Barcelona Supercomputing Center, the University ofOxford,theUniversityofGeneva,theUniversityofSheffield,andUniversitatPompeuFabra.Ourever-growinglistofassociatepartnersalsoincludesmanyacademicinstitutions,includingBirmingham City University, Brunel University, Rugers University, Leibniz SupercomputingCentre, University of Leeds, the VPH Institute, Zayed University, Heidelberg Institute forTheoretical Studies, and the Hartree Centre. These will be leveraged to disseminateCompBioMed’smissionandactivity.

6.2 IndustryCompBioMed will target the HPC and biomedical (including pharmaceutical) industries,includingsoftwareandhardwareresourceusers,resourceproviders,developers,researchers,CEOsandotherleaders.TheCoEwillbetoactasaninnovationincubator.AcademiawillworkwithindustrytoexploittheCoE’scapabilitiesbyraisingawarenessofandprovidingsupportwithinindustrialcontextsespecially, but by nomeans exclusively, in SMEs. This is a key activity to ensure the widerimpact of HPC in this sector. It will include meaningful intellectual engagement betweenexpertsworkinginacademiaandusersbasedinindustry,withknowledgeofHPCandanabilitytofacilitateaccesstotheappropriatescaleofresourcesrequired.Ourdisseminationchannelsand involvement in events (described in Sections 8 and 9) will also target industrystakeholders.ThepharmaceuticalindustryisrepresentedbyourengagementwithcorepartnersEvotecandJanssen, as well as our associate partners Convergence and GSK. Also included in ourconsortiumare LifeTecGroup, an innovativemedical devicedevelopment and contractR&DSME;Acellera,anR&Dcompany thatprovidesnewtechnologies for thestudyofbiophysicalphenomena; and DNAnexus, a company that provides a global network for sharing andmanagementofcomputationaltoolsrunninginahighlysecureenvironmentforindustrialandclinicalapplications.WewilltrackworkdonebytheAmericanSocietyofMechanicalEngineers(ASME)sub-committeeontheverificationandvalidationofmodellingandsimulationforthedesignandassessmentofbiomedicalproducts(V&V-40),andtherelatedUSAFDAFastTrackinitiative,fortheuseofcomputermodellingandsimulationresultsinregulatoryprocesses.We




will also monitor the work of the European Federation of Pharmaceutical Industries andAssociations(EFPIA)withtheEuropeanMedicineAgency(EMA)inrelationtopharmaceuticalproducts.WewilltrackworkdonebytheASMEsub-committeeV&V-40ontheverificationandvalidationofmodellingandsimulationforthedesignandassessmentofbiomedicalproducts,and the related USA FDA Fast Track initiative, for the use of computer modelling andsimulation results in regulatory processes. We will also monitor the work of the EuropeanFederationofPharmaceutical IndustriesandAssociations(EFPIA)withtheEMAinrelationtopharmaceuticalproducts.Through the involvement of our industry partners, we also expect to disseminate theimportanceof computer based, predictive,multiscalemechanisticmodelling andhow it canimpactondrugdesigninanincreasinglypersonalisedenvironment,andtoco-designindustry-orientedadded-valueworkflowsthatwillcontributetothelong-termsustainabilityoftheCoE.The importance of serious compute capability is represented through our partnership withBull/ATOS.Despite the inexorable advances in medical science, the cost of discovery and bringing tomarketofnewdrugsisnowvergingontheprohibitive.ThepharmaR&Dmodelisundermorepressure to implement cost cutting efficiencies than ever before. Compounding this is thetrend toward stratification and patient specific medical treatment, meaning for any givenailmentoneshouldinfutureexpecttohaveonoffermultipledrugs,eachbeingoptimisedforagroupofindividuals,basedontheirgenotypicandphenotypicprofile.Ourmolecularmedicineexemplarresearchstrandaimstoassistwiththisnewapproach,showinghowit isbecomingpossible,basedonmodernHPCcapabilities, toaccelerate thediscoveryofnewdrugs,whilepayingcloseattentiontogeneticprofiling.OurpartnerEvotecisadrug-discoveryallianceanddevelopmentpartnershipcompanyfocusedon rapidly progressing innovative product approaches with leading pharmaceutical andbiotechnology companies. It has several significant long-term discovery alliances with well-established industry players such as Bayer, Boehringer Ingelheim, the CHDI Foundation,Genentech, Janssen Pharmaceuticals, AstraZeneca and Ono Pharmaceuticals. Evotec will beresponsible for integration of our state-of-the-art GPCR modelling technology with an HPCplatform. This expertise will be made available within the CoE and to third parties seekingassistancefromtheCoE,anddirectlyfromEvotec.Theadaptationofthesecomputationaldrugdiscovery protocols toHPCwillmake theGPCR drug-discovery processmuchmore efficientandcosteffective,potentiallyhavingalargeeffectontheentirepharmaceuticalsectorgiventhecentralimportanceofGPCRbaseddrugtargets.Evotecwilldisseminatetheresultsoftheworktopartnerpharmaceuticalandbiotechnologycompaniesinordertostimulatefollow-onresearch, making written publications and also encouraging company presentations atinternationalconferences.

6.3 TheClinicCompBioMedwillalsotargetitsclinicalstakeholders,includinghealthcareprofessionalssuchasdoctorsandsurgeonsandthoseworkingwithITinhealthcare.Weexpect that computationalmodellingof thehumanbodyandphysiologywill impact thefield of biomedicine by fundamentally altering the basis for the diagnosis and treatment ofdisease intoapersonalised,predictive,participatoryandpreventativeprocess. In the future,




medicalinnovationwillbedirectedtowardsoptimisingtreatmentsusingintegratedfunctionalsimulation in silico,assemblingacustomisedcomputermodelofapatient'sconditionacrossmultiple organ systems and length scales (frommolecular to human to population), acrosstimescalesfromnanosecondstoyears,andallowingfortheinfluenceoftheenvironment.The quality and usability of our software will put us in an influential position in terms ofpromoting modelling and associated software standards internationally. The presence ofclinical partners within our bid will ensure that we exploit any potential impact of thesemodellingtools inaclinicalcontext.Through integration inclinicaldecisionsupportsystems,computerbasedmodellingandsimulationwillbefurnishadvisorycoursesofactionaheadoftreatments, including interventions, whichwill lead to improved outcomes for patients andenhancethehealthandwellbeingofthecitizensofEuropeanUnionaswellasglobally.An important impactof the in silico technologieswearepromotingwillbe to reduce, refineandeventuallyreplaceanimalexperimentation inbiomedicalresearch,puttingsimulationonan equal footing with sequencing and imaging. Various computational biomedicine projectsthat have developed advanced technologies are struggling to move to clinical trials phasesbecausethetechnologicalexpertiseislackingwithinmanyresearchhospitals.However,onceanyoneofthesecomputationalworkflowsisestablishedandputinuseinaclinicalsetting,itispossible to amass hundreds of patient-specific simulations. Even if the primary data mightneed to be destroyed on grounds of privacy, these data can be used to identify inputparameter distributions that characterise well in silico populations, with respect to theparticular pathophysiological process captured by the simulation. If these data can becombinedwithasimulationofan intervention,whatweobtainareso-called ‘insilicoclinicaltrials’, wherein a new surgical procedure, the insertion of a new medical device, or thetreatmentwithnewdrugs is simulatedwithinmodels of hundredsor thousandsof “virtual”patients and/or real people. Likewise, interpolations can be performed over the inputparameterdistributionsthatrepresentrealisticindividualpatientswithhighfidelity.This cutting-edge biomedical R&D technology, involving collaboration between industry andacademia, is set to play a key role in promoting EU prosperity and growth. There is realpotential to increase the amount of internationally funded R&D taking placewithin the EU,whichcouldstimulateareshapingoftheEU-widepharmaceuticalindustry.Inamorespecificsense,ourCoEwillprovideauniqueopportunitytogeneratenewnetworksandpartnershipsand to promote current biomedical research and its applications within drug discovery. Amajorimpactofthisresearchwillbethediscoveryofmoreeffectivemedicinesthatareclearof harmful side effects and improve the health and lives of people bothwithin the EU andacrosstheglobe.Inaddition,onlythiskindofresearchcanleadtothereductionandeventualremovalofanimaltestinginresearch.Wewillalsotargettheclinicthroughourassociatepartner,theAvicennaAlliance.Avicennaisa Support Action co-funded by the European Commission which kicked off its activities inOctober 2013 with the goal of creating a Roadmap for in silico clinical trials. The Avicennacommunityincludes37companies,mostlySMEs,whichprovide insilicoclinicaltrialsservicesofsomekindtothebiomedicalindustry.MostofthesecompaniesshouldprovetobenaturalbusinesspartnersforCompBioMed,astheycanmarkettheirservicesinanenhancedmannerifsupportedbyourCoE.Inaddition,ourdisseminationchannelsandinvolvementinevents(describedinSections8and9)willalsotargetclinicalstakeholderswhereappropriate.




6.4 RegionswithFewerHPCResourcesTo perform outreach to and engagement with countries and regions within the EU andassociated states with fewer HPC resources, CompBioMed will collaborate with the COST(European Cooperation in Science and Technology – see www.cost.eu) platform, throughtrans-European networking of research. COST is based on a European intergovernmentalframework for Co-operation in Science and Technologywith 36Member Countries and oneCo-operatingState.ItalsoencouragesactiveparticipationbyinstitutionsfromNearNeighbourCountries and International Partner Countries. Near neighbour countries include Armenia,Russia,Ukraine;Lebanon,Libya,PalestineAuthority,Jordan,Syria,Tunisia,EgyptandAlgeria,while Turkey is currently seeking membership. Bosnia & Herzogovina are also beingconsidered. Several CompBioMed partners (e.g UCL, UvA) are already participants in theOpenMultiModCOSTActionCA15120onOpenMultiscaleSystemsMedicineandplan toco-organisemeetings in order to promote increasing interactions in this domain.We shall alsoworkwithotherfundedCoEsandtheEXDCIprojecttoachieveimpactsoastoraisetheprofileofandfacilitateaccesstoHPCinsuchcountries.Another important aspect is the wider international outreach of CompBioMed, which isassured through the strong linksofmanypartnerswithUSA, LatinAmericanandSouthEastAsian countries, especially in the biomedical research domain. In addition to theaforementionedprojectsandinitiatives(EU-Brazil,JLESC,etc.)itisalsoworthmentioningtheexistenceofmanydirect research linksofCompBioMedpartnerswithnon-Europeanregionsthrough teaching, training, MoUs, agreements with hospitals and biomedical organizations,hostingofPhDstudentsandpostdocs,etc.TheselinksareparticularlyrelevantforthecaseoflessdevelopedLatinAmericancountries.BSC is a founding member of the Joint Laboratory for Extreme-Scale Computing (JLESC,http://publish.illinois.edu/jointlab-esc/) which focuses on software challenges arising inextremescalehigh-performancecomputers, includingbiomedicalresearch.JLESCreachgoeswell beyond the European scientific ecosystem: it includes international partners such asRIKEN(Japan),KISTI(SouthKorea),UniversityofIllinois,NCSAandArgonneNationalLab(USA).Additionally, BSC takespart in several EU-Brazil joint projects.Notably, it is a partner in theEUBrazil-CloudComputingproject,wheretogetherwithLNCC(Brazil)itisworkingonausecaseforthecardiovascularsystem.

6.5 GeneralAudiencesCompBioMed will target general audiences (high school students, general public, etc). Thegeneralpublicwillnodoubtbe interested inhowcomputationalbiomedicinecanconnecttotheclinicandbenefitthemselvesaspotentialclinicalpatients,whilehighschoolstudentswillalsobeinterestedincomputationalbiomedicineasaneducationalpathway.The CompBioMed Associate Partner, the Science Museum, is a major museum in SouthKensington, London. The Science Museum has a substantial online presence on top of itsphysical location in London where various events and actions connecting science to thegeneral public occur. The presents powerful opportunities for CompBioMed to harness, andwewilltakefulladvantageofthisrelationship.




Weareconsideringseveralapproachesfortargetinggeneralaudiences.Wewill,forexample,produce content for popular science magazines such as New Scientist, and participate ingeneralpubliceventssuchastheRoyalSocietyExhibitioninLondon.

7 BrandingandDisseminationMaterialsTheCompBioMedbrandwillbeusedinallofourdisseminationmaterials,beitintheformofleaflets,posters,whitepapersetc.Templateswillbecreatedforeachdisseminationmaterialtype inorder toencouragerecognitionof theCompBioMedbrandand therefore theprojectand itsaims.ThetemplatesarecurrentlyavailableontheCompBioMedwebsite intranet forprojectdeliverablestotheEuropeanCommission.ConsortiummembersarerequiredtoinformCBK of content produced using these templates. All presentation slides frommeetings andconferenceswill become available on the CompBioMedwebsite intranet subsequent to theevents taking place, which may be used as templates for future presentations on theCompBioMed project. Consortiummembers are permitted tomodify the templates but thefinalproductmustcontaintheCompBioMedlogo,thestatementacknowledgingtheEuropeanCommission,andtheEuropeanFlag.Task3.3isconcernedwiththeproductionofdisseminationmaterialsandrunsthroughouttheproject. During the course of the project CompBioMed will create White Papers (incollaboration with task 4.2) as well as other dissemination materials and will make themavailableviatheweb.CompBioMedwillalsodisseminate,viathewebsiteandotherchannels,thescientificpublicationsresultingfromtheproject’sresearch.Additionally,flyersandposterswillbeproducedandmadeavailableatworkshopsandconferencessuchasSupercomputingConference, International Supercomputing Conference, Virtual Physiological HumanConference,andInternationalConferenceonComputationalScience.

7.1 ProjectLogoTheCompBioMed logohasbeendesignedtobeclean,clear,andrecognisable,withastrongimageandstyle.ThelogoaimsforsimplicitywhilesubtlyhintingatCompBioMed’smissionofcomputational (represented by the classic ‘computer’ font) biomedical research (hinted atthroughtheDNArepresentation)relatedtothehumanbody(representedbyahumanfigure).Thelogoisshownbelow:




Figure1:TheCompBioMedLogo(‘standard’version)

Insomecircumstances,thetextinthelogomayneedtoberelativelylargerwithintheimage,for instance when there is not much height available, but plenty of width. For thosecircumstances, an alternate ‘header’ version of the logo has been prepared, this is shownbelow:

Figure2:TheCompBioMedLogo('header’version)

The logos are available in .png graphical format and .ai vector format, in high and lowresolution.

7.2 LeafletsLeafletshavebeenandwill continue tobemadeandhandedout to stakeholdersatvariousevents(conferences,workshops,seminarsetc),withthepurposeofmakingthemawareoftheprojectorparticularaspectsof it. Inparticular,one leaflet summarisesCompBioMedand itsaims,anditcontainsthefollowing:

• CompBioMedlogo• AURLtotheCompBioMedwebsite• AlinktotheCompBioMedtwitteraccount• Thefundingline“ThisprojecthasreceivedfundingfromtheEuropeanUnion’sHorizon

2020researchandinnovationprogrammeundergrantagreementNo675451.”• AnimageoftheEuropeanflag• AsummaryoftheCompBioMedproject• Theexpectedoutcomes• Theexpectedimpact• ImagesofCompBioMedresearch




7.3 PostersCompBioMedpostersarealreadybeingpreparedtopresentateventssuchasconferencesandworkshops.ThesewilldisplayspecificaspectsofCompBioMedresearchandoutcomesandwillrequire a CompBioMed consortiummember to explain furtherwhat appears on the poster,whichwillcontain:

• TheCompBioMedlogo• AURLtotheCompBioMedwebsite• Thefundingline“ThisprojecthasreceivedfundingfromtheEuropeanUnion’sHorizon

2020researchandinnovationprogrammeundergrantagreementNo675451.”• AnimageoftheEuropeanflag• ImagesofCompBioMedresearch• SummariesofCompBioMedresearchandoutcomes

7.4 PresentationsMembersoftheCompBioMedconsortiumwillattendandpresenttalksatvariousconferences,workshopsandseminarsthroughouttheproject.Whereappropriate,theslidesforsuchtalkswillcontainasectionorslidewhichsummarisestheCompBioMedproject.Thesewillcontain:

• CompBioMedlogo• AURLtotheCompBioMedwebsite• Thefundingline“ThisprojecthasreceivedfundingfromtheEuropeanUnion’sHorizon

2020researchandinnovationprogrammeundergrantagreementNo675451.”• AnimageoftheEuropeanflag

Inothercases,itwillbeappropriatetothemeallofthetalkslidesasCompBioMedrelated.Intheseinstances,atemplateisavailablethatdisplaystheCompBioMedlogooneachpage,andtherestoftheslideaesthetichasbeenadjustedtomatchthatofthelogo,asshownbelow:

Figure3:CompBioMedSlideTempate




7.5 ScientificPapersThroughout theproject, theCompBioMedconsortiumwillpublishnumerousscientific,peer-reviewed papers, conference proceedings, and chapters in books. Such publications willcontainthefollowingpassage:“This project has received funding from the European Union’s Horizon 2020 research andinnovationprogrammeundergrantagreementNo675451.”

7.6 OtherDisseminationMaterialsCompBioMed will harness novelty branded items that will be distributed at various eventsduring the project. This will act to enhance the awareness of the project. Such items willincludecustomstressballsinvariousmedicalshapes,pens,mugs,and/orUSBsticks;eachwillbebrandedwiththeCompBioMedlogo.

8 DisseminationChannelsInthissectionthevariousdisseminationchannelsavailabletoCompBioMedaredescribed.Ingeneral,weaimtomakemaximumuseofalreadyestablishedpartner,national,andEuropeandisseminationchannelssuchasE-infrastructurespecialistgroups,thusmaximisingtheimpacttocostratioofourdisseminationactivitiesinworkpackage3.As a principle of practice we will employ leverage in dissemination wherever we find theopportunity – in engaging channels and mechanisms previously funded by EU investment,and/or already established in the partner institutions and in professional associations andworkinggroupswherethekeymembersofCompBioMedarealreadypresent.Task 3.2: Maintaining the CompBioMed Online Presence, is connected to harnessingCompBioMed’s dissemination channels. The taskprimarily concerns theprojectwebsite andtwitter account, and runs throughout the project. Also related is Deliverable D3.1 (andMilestone3):WebsiteRelease,whichwassubmittedinmonth2oftheproject.

8.1 TheCompBioMedWebsiteAt the core of our dissemination activity is the CompBioMedwebsite, where the project isdescribed,itsvariouspartnersarelisted,itsactivitiesarereported,helpfulcontactdetailsareprovided,andwherethereisarepositoryfortheproject’strainingprogrammeandforproject-related documents generally. The website can be accessed at the URLhttp://www.compbiomed.eu/.Thewebsite isaddressed indetails inD3.1:WebsiteRelease,whichisavailableonthewebsitesintranet.




8.2 SocialMediaCompBioMedaimstohaveaneffectivesocialmediapresence.At the forefrontof this is theCompBioMedTwitteraccount,whichcanbefoundat@bio_comp.Thetwitteraccountwillbeusedtodisseminateoureventsandactivity,andthatofourcoreandassociatepartners.WewillconsiderotherpotentialsocialmediaavenuessuchasLinkedInandYoutube.Theproject’sTwitteraccountisshowbelow:

Figure4:TheCompBioMedTwitterAccount

8.3 MailinglistsCompBioMedmailing listshavebeen setup toaid communicationwithin theproject. Theseallowcommunicationtoeveryoneintheconsortiumandtoeveryonewithinaparticularworkpackage.Wewilladdadditionalmailinglistsasrequired.Themailinglistsareshownbelow:AllCompBioMedpartners: [email protected]: [email protected]: [email protected]: [email protected]: [email protected]: [email protected]: [email protected]: [email protected]: [email protected]




WorkPackage5: [email protected]: [email protected] [email protected]: [email protected]: [email protected]

8.4 RelatedProjectsAs described in Subsection 6.4, we have partnered with the COST action “OpenMultiscaleSystems Medicine", abbreviated as OpenMultiMed, which will also act as a wide reachingdisseminationchannel forCompBioMed.Otherrelatedprojectsthatwehavepartneredwithandwillharnessasdisseminationchannelsinclude:

• BioExcel - aCentreof Excellence forprovisionof support to academic and industrialresearchers in the use of high-performance computing (HPC) and high-throughputcomputing(HTC)inbiomolecularresearch.

• ETP4HPC - theEuropeanTechnologyPlatform (ETP) in theareaofHigh-PerformanceComputing (HPC). It is an industry-led think-tank comprising of European HPCtechnologystakeholders:technologyvendors,researchcentresandend-users.

• EXDCI – The European Extreme Data & Computing Initiative to support thedevelopment and implementation of a common strategy for the European HPCEcosystem.

• MaX-Auser-focused,problem-orientedEuropeanCentreofExcellence,whichworksatthefrontiersofcurrentandfutureHighPerformanceComputing(HPC)technologies,toenablethebestuseandevolutionofHPCforresearchandinnovation.

9 EventsCompBioMedwillorganizeandparticipateinmanyeventsthroughouttheproject’sduration,includingconferences,workshops,seminars, trainingeventsandmore.CompBioMed’seventinvolvementisconnectedtoTask3.6:Conference/WorkshopPlanning,whichrunsthroughoutthedurationoftheproject.

9.1 EventOrganisationWP3 will organise two major events. Firstly, we will coordinate with the EU funded COSTAction:OpenMultiModtoco-organiseaworkshopwithathemethatalignswithCompBioMedandOpenMultiMod.Secondly,wewillorganiseonededicatedworkshopontheuseofHPCincomputationalbiomedicine.Thededicatedworkshopwillbeco-locatedwithalargerinternationalconferencesuchasthebiennialVPHconference,theyearlyICCSconference,oranothermajorconference,toensureourCoE’s activitieswithin Europeandbeyond. This is aidedby theCoEpartnership’s strongties to thecomputationalbiomedicinecommunityandknowledgeof relevantevents in theirrespective institutions. The dedicated CompBioMed workshop will have as objectives topromote CompBioMed results and success stories and to provide use cases to interested




audiences.Thistaskincludestheactualworkshoporganisation,includingliaisonwiththehostconference,making calls for papers, reviewing, and so on.We are also keen to include livedemonstrator projects, using themost advancedHPC andVirtual Reality setups possible, toshowcasewhatHPChastooffertothecommunity.Inaddition,weintendtocreateaspecialissue of a journal related to this workshop, and to create high impact outreach anddisseminationmaterial.Beyond the major events described above, we will organise other events to meetCompBioMed’sneeds.Onesucheventwilloccurwithin the firstyearof theprojectandwillinvolvecommercialHPCandCloudproviders (e.g.AWS,MSAzure,DNAnexus,HarteeCentreand so on) as well as conventional HPC providers in the project, along with the end userswithintheprojecttodeterminetheneedsandresourcesavailableviaCompBioMedintermsofCloudandHPC.

9.2 EventParticipationWork Package 3 is responsible for coordinating the participation of the CompBioMedconsortium in variousworkshopsand conferences. Events aligningwithCompBioMed’s aimswillbeidentifiedandhighlightedtotheprojectconsortium.Whereappropriate,attendanceatevents of significance will be coordinated to include a strong contingent of CompBioMedrepresentatives. Events in the first year of the project thatwewill consider participating ininclude:

• BioExcel,GROMACShackathon2016,17-19Oct2016,Barcelona,Spain• BioExcel:workflowtrainingforcomputationalbiomolecularresearch20-21Oct,2016,

Barcelona,Spain• e-COSTOpenMultiMedMCmeeting,20-21Oct2016,Skopje,Macedonia• 1stConferenceoftheEuropeanAssociationofSystemsMedicine(EASyM),26th–28

Oct2016,Berlin,Germany• BioExcelall-handsmeeting:3-4Nov2016,Barcelona,Spain• Supercomputing2016(SC16),14-17Nov2016,Utah,USA• E-CAM:ExtendedSoftwareDevelopmentWorkshop:TrajectorySampling,14-25Nov

2016,Traunkirchen,Austria• Symposium inAdvancedNanomaterials forBiomedicalApplications,20-21Feb2017,

Sheffield,UK• The5thInternational Conference on Computational and Mathematical Biomedical

Engineering(CMBE17),10-12Apr2017,Pittsburgh,USA• EuropeanHPC SummitWeek 2017 (plus PRACEdays), 15 – 19May 2017, Barcelona,

Spain• Supercomputing2017(SC17),Denver,USA• ICCS2017,12–14Jun2017,Zürich,Switzerland• ISC2017,Jun2017,Frankfurt,Germany

In the first year of the project, we will have significant participation in the European HPCSummitWeek2017,15th to19thMay2017,Barcelona, Spainand ISC2017,18th to22nd June,Frankfurt, Germany. For this, we will be assisting with the reviewing of abstracts and theadvertisingof theevent,andwehavebeenallottedadedicatedsession forCompBioMed inthePRACEdaysScientificParallelTrackonTuesdayMay16th2017.




Disseminationmaterialswillbeproducedandmadeavailableatworkshopsandconferencessuch as Supercomputing, International Supercomputing, Virtual Physiological Human, andInternationalConferenceonComputationalScience.

10 TrainingTrainingeventsandmaterialsareamajorpartofWP3andofCompBioMed.Wewilldeveloptraining courses and online training materials in collaboration with project softwaredevelopers and HPC experts. Additionally, CompBioMedwill run hands on training courses,andraiseawarenessonthechallengesandopportunitiesofHPCinthefieldofcomputationalBiomedicine with all stakeholders, as well as provide tailored training to academic andindustrialresearchers,andclinicalusers.CompBioMed’strainingplanwillbeaddressedindetailinD3.3:TrainingPlan,whichisdueinmonth6oftheproject.Thereportwillincludebothtrainingevents,meansofdelivery,andthepartnersresponsibleforthetraining.

11 AssociatePartnerEngagementAsmentionedthroughoutSection6,CompBioMed’sassociatepartnersplayakeyrole inouroutreach to the project’s stakeholders, in addition to providing their own resources andwisdomthatwillhelptheprojectdeliveritsgoals.Inordertomaintaintheassociatepartners’engagementintheproject,wewilloffervariousformsofinvolvementinCompBioMed,liaisewiththemregularly,andofferbenefitstotheirpartnership.Theseinclude:

• AccesstoandprovisionofcertainHPCresources• Accesstosoftware• Accesstotrainingmaterials• Invitationtofutureprojectmeetingsandworkshops• IndustrialAPsinvitedtobemembersoftheindustrialadvisoryboard• ParticipationintheInnovationExchangeProgramme• ParticipationinIncubatorCoordination• Distributionofaquarterlynewsbulletin

We have set up amailing list for the associate partners as a channel to communicatewiththem.

12 ReportingofDisseminationActivityIn executing CompBioMed’s dissemination plans there must be regular communicationbetweenallofthepartners,inparticularviaCBKwhoaremanagingthedisseminationaspectsofWP3, toensure thatactivity is correctly recorded.The followingpointsdefinehow this isimplemented:

• Inthefirst instance,keyachievements,events,publications,mediaappearances,andanyactivitiesthatshouldbedisseminated,willbereportedtoCBK,[email protected].




• In order to monitor the above activity, CBK will use the monthly WP LeaderTeleconferences to check on any unreported activity, allowing for it to bedisseminatedadequately.

• The monthly WP Leader Teleconferences will also be used for CBK to report alldissemination activity from that month to the principal investigator and projectmanagerofCompBioMed.

• The annual dissemination reports will document all CompBioMed disseminationactivity from that year, and will aid in the annual updating of this document, theCompBioMedDisseminationActionPlan.

Work package leaderswill arrange summaries of deliverables and research outcomes to bedeliveredtoCBKfordistributiononCompBioMed’sdisseminationchannels.

13 OutputMeasurementAttheendoftheprojectwewillwanttogetanideaofhoweffectiveourdisseminationoutputhasbeen.Togetperformance indicators,wewillkeeprecordsofhowmanyeventswehaveparticipatedin,whotheaudiencewas,howbigtheaudiencewas,howbigtheaudiencewasfor our posters, howmany took our leaflets, registered for our training events, howmanywhite papers we produced, numbers for downloads of our software and publications, andgaugeourinfluenceinsocialmediabytrackingfollowersontheplatformswewillparticipatein. We will also be able to track progress in attracting attendees to our workshops bybenchmarking thesecondeventagainst the first.Thenumberofpublications, their journals’impactfactors,andthenumberofcitationsreceivedwillalsogiveameasureofeffectiveness.CompBioMed intendstogatherasmuch informationtomeasure impactaspossible.Wewillcontinually research published best practice in impact measurement from Horizon 2020projects and other sources to establish appropriate metrics for this measurement. Forexample,theEuropeanCommissionliststhefollowingasexamplesofoutputmeasurement:

• Evidenceofdebatesinthemedia• Evidenceofnewfundersforyourarea• Evidence of transfer of research and innovation into practice (patents,

prototypes,licenses)• Number and turnover of new products, practices or procedures developed,

basedonyourresearchoutcomes• Numberofarticlesinthepress• Numberofpeopleaskingforfeedbackormoreinformation• Numberofreferencesinscientificpublications• Participationinprojecteventsandseminars• Speakerevaluationsfromconferencepresentations• Surveyofend-users• Trendsinwebsitevisits

Wewillalsoconsiderusingalternativemetricstogagethereachofourpublications.Altmetric(www.altmetric.com) is a service that tracks non-journal citation impact; here a score isprovidedwhichactsasaquantitativemeasureoftheattentionthatapublicationoreventhasreceivedviasocialmedia.Theimpactismeasuredintermsofthearticlesbeingmentionedorlinked to in social media, articles, blogs and websites, and is adjusted according to thesignificanceandrelevanceofthatsource.




13.1 KeyPerformanceIndicatorsInadditiontotheperformance indicatorsmentionedabove,CompBioMed isalsocommittedtoalistofKeyPerformanceIndicators(KPIs).ThreeoftheseKPIsrelatedtodisseminationandarelistedbelow:

• Number of people attending the two workshops events organised by WP3: 50attendeesperworkshop.�

• Numberofpublicationsinpeer-reviewedinternational journalsthatacknowledgethesupportofCompBioMed.Target:by theendof the three-yeardeploymentphase,atleast 10 publications (two in impact factor ten or higher journals) from 5 differentresearchgroupingswiththeCoE.�

• Number of companies engaged. Target: by the end of the three-year deploymentphase,at least20companies,at least30%beingSMEs,haveaccessedCompBioMedservices.�

WewilltracktheseKPIsandreportonthemineachannualdisseminationreport.

14 AftertheProjectAside from the dissemination activities conducted during the project, we will keepCompBioMed ‘alive’ in the community after the project’s termination. We will do so bypublicising our training material and encouraging participation of the consortium in futureeducationalevents.ThemembersoftheCompBioMedconsortiumwillalsobeencouragedtopresent work conducted during the project at future conferences. Our publications andsoftwarewillstillbenefitthecommunityaftertheprojectends,wheretheresultswillremainavailable on the website until 5 years after the project ends. We will also explore fundingopportunities during theproject thatwill allowus to continue theCentre of Excellence in anewphaseorform,immediatelyfollowingtheconclusionofthisproject.

15 ConclusionsWe believe that, through our dissemination activities, expected impacts will be acceleratedand strengthened. Through the dissemination of CompBioMed’s research findings and thedistribution and awareness of its software to academia, industry and clinics alike, we willcontributetothestrengthandleadershipoftheEUinHPCtechnologies,alsohavinganimpacton the emerging HPC markets. Through the building of networks between our scientificcommunity and the encouragement of collaboration activities, in addition to our trainingagenda, we will accelerate European excellence in software and algorithms in a multi-disciplinaryfashion.Also,webelievethatthroughtheeffectivecommunicationofourworkto




standardisationbodies,wewill be able to jointlydevelopnew standardswhere theydonotexist.Thisactionplanisa‘livingdocument’thatwillbeupdatedthroughouttheproject,asrequired.We will adapt the dissemination activity of our Centre of Excellence in order to mosteffectivelymeetthechallengeswefaceincarryingoutourmission.

Documents

D3.2 Dissemination Action Plan · 2017-03-31 · D3.2 Dissemination Action Plan PU Page 2 Version 1.1 “This project has received funding from the European Union’s Horizon 2020